Cargando…

3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals

Background: Radiolabeled somatostatin analogues (e.g. [(68)Ga]Ga-DOTATATE and [(177)Lu]Lu-DOTATATE) have been used to diagnose, monitor, and treat neuroendocrine tumour (NET) patients with great success. [(18)F]AlF-NOTA-octreotide, a promising (18)F-labeled somatostatin analogue and potential altern...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahenkorah, Stephen, Murce, Erika, Cawthorne, Christopher, Ketchemen, Jessica Pougoue, Deroose, Christophe M., Cardinaels, Thomas, Seimbille, Yann, Fonge, Humphrey, Gsell, Willy, Bormans, Guy, Ooms, Maarten, Cleeren, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373814/
https://www.ncbi.nlm.nih.gov/pubmed/35966589
http://dx.doi.org/10.7150/thno.75336
_version_ 1784767666986156032
author Ahenkorah, Stephen
Murce, Erika
Cawthorne, Christopher
Ketchemen, Jessica Pougoue
Deroose, Christophe M.
Cardinaels, Thomas
Seimbille, Yann
Fonge, Humphrey
Gsell, Willy
Bormans, Guy
Ooms, Maarten
Cleeren, Frederik
author_facet Ahenkorah, Stephen
Murce, Erika
Cawthorne, Christopher
Ketchemen, Jessica Pougoue
Deroose, Christophe M.
Cardinaels, Thomas
Seimbille, Yann
Fonge, Humphrey
Gsell, Willy
Bormans, Guy
Ooms, Maarten
Cleeren, Frederik
author_sort Ahenkorah, Stephen
collection PubMed
description Background: Radiolabeled somatostatin analogues (e.g. [(68)Ga]Ga-DOTATATE and [(177)Lu]Lu-DOTATATE) have been used to diagnose, monitor, and treat neuroendocrine tumour (NET) patients with great success. [(18)F]AlF-NOTA-octreotide, a promising (18)F-labeled somatostatin analogue and potential alternative for (68)Ga-DOTA-peptides, is under clinical evaluation. However, ideally, the same precursor (combination of chelator-linker-vector) can be used for production of both diagnostic and therapeutic radiopharmaceuticals with very similar (e.g. Al(18)F-method in combination with therapeutic radiometals (213)Bi/(177)Lu) or identical (e.g. complementary Tb-radionuclides) pharmacokinetic properties, allowing for accurate personalised dosimetry estimation and radionuclide therapy of NET patients. In this study we evaluated 3p-C-NETA, as potential theranostic Al(18)F-chelator and present first results of radiosynthesis and preclinical evaluation of [(18)F]AlF-3p-C-NETA-TATE. Methods: 3p-C-NETA was synthesized and radiolabeled with diagnostic ((68)Ga, Al(18)F) or therapeutic ((177)Lu, (161)Tb, (213)Bi, (225)Ac and (67)Cu) radionuclides at different temperatures (25-95 °C). The in vitro stability of the corresponding radiocomplexes was determined in phosphate-buffered saline (PBS) and human serum. 3p-C-NETA-TATE was synthesized using standard solid/liquid-phase peptide synthesis. [(18)F]AlF-3p-C-NETA-TATE was synthesized in an automated AllinOne® synthesis module and the in vitro stability of [(18)F]AlF-3p-C-NETA-TATE was evaluated in formulation buffer, PBS and human serum. [(18)F]AlF-3p-C-NETA-TATE pharmacokinetics were evaluated using µPET/MRI in healthy rats, with [(18)F]AlF-NOTA-Octreotide as benchmark. Results: 3p-C-NETA quantitatively sequestered (177)Lu, (213)Bi and (67)Cu at 25 °C while heating was required to bind Al(18)F, (68)Ga, (161)Tb and (225)Ac efficiently. The [(18)F]AlF-, [(177)Lu]Lu- and [(161)Tb]Tb-3p-C-NETA-complex showed excellent in vitro stability in both PBS and human serum over the study period. In contrast, [(67)Cu]Cu- and [(225)Ac]Ac-, [(68)Ga]Ga-3p-C-NETA were stable in PBS, but not in human serum. [(18)F]AlF-3p-C-NETA-TATE was obtained in good radiochemical yield and radiochemical purity. [(18)F]AlF-3p-C-NETA-TATE displayed good in vitro stability for 4 h in all tested conditions. Finally, [(18)F]AlF-3p-C-NETA-TATE showed excellent pharmacokinetic properties comparable with the results obtained for [(18)F]AlF-NOTA-Octreotide. Conclusions: 3p-C-NETA is a versatile chelator that can be used for both diagnostic applications (Al(18)F) and targeted radionuclide therapy ((213)Bi, (177)Lu, (161)Tb). It has the potential to be the new theranostic chelator of choice for clinical applications in nuclear medicine.
format Online
Article
Text
id pubmed-9373814
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-93738142022-08-12 3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals Ahenkorah, Stephen Murce, Erika Cawthorne, Christopher Ketchemen, Jessica Pougoue Deroose, Christophe M. Cardinaels, Thomas Seimbille, Yann Fonge, Humphrey Gsell, Willy Bormans, Guy Ooms, Maarten Cleeren, Frederik Theranostics Research Paper Background: Radiolabeled somatostatin analogues (e.g. [(68)Ga]Ga-DOTATATE and [(177)Lu]Lu-DOTATATE) have been used to diagnose, monitor, and treat neuroendocrine tumour (NET) patients with great success. [(18)F]AlF-NOTA-octreotide, a promising (18)F-labeled somatostatin analogue and potential alternative for (68)Ga-DOTA-peptides, is under clinical evaluation. However, ideally, the same precursor (combination of chelator-linker-vector) can be used for production of both diagnostic and therapeutic radiopharmaceuticals with very similar (e.g. Al(18)F-method in combination with therapeutic radiometals (213)Bi/(177)Lu) or identical (e.g. complementary Tb-radionuclides) pharmacokinetic properties, allowing for accurate personalised dosimetry estimation and radionuclide therapy of NET patients. In this study we evaluated 3p-C-NETA, as potential theranostic Al(18)F-chelator and present first results of radiosynthesis and preclinical evaluation of [(18)F]AlF-3p-C-NETA-TATE. Methods: 3p-C-NETA was synthesized and radiolabeled with diagnostic ((68)Ga, Al(18)F) or therapeutic ((177)Lu, (161)Tb, (213)Bi, (225)Ac and (67)Cu) radionuclides at different temperatures (25-95 °C). The in vitro stability of the corresponding radiocomplexes was determined in phosphate-buffered saline (PBS) and human serum. 3p-C-NETA-TATE was synthesized using standard solid/liquid-phase peptide synthesis. [(18)F]AlF-3p-C-NETA-TATE was synthesized in an automated AllinOne® synthesis module and the in vitro stability of [(18)F]AlF-3p-C-NETA-TATE was evaluated in formulation buffer, PBS and human serum. [(18)F]AlF-3p-C-NETA-TATE pharmacokinetics were evaluated using µPET/MRI in healthy rats, with [(18)F]AlF-NOTA-Octreotide as benchmark. Results: 3p-C-NETA quantitatively sequestered (177)Lu, (213)Bi and (67)Cu at 25 °C while heating was required to bind Al(18)F, (68)Ga, (161)Tb and (225)Ac efficiently. The [(18)F]AlF-, [(177)Lu]Lu- and [(161)Tb]Tb-3p-C-NETA-complex showed excellent in vitro stability in both PBS and human serum over the study period. In contrast, [(67)Cu]Cu- and [(225)Ac]Ac-, [(68)Ga]Ga-3p-C-NETA were stable in PBS, but not in human serum. [(18)F]AlF-3p-C-NETA-TATE was obtained in good radiochemical yield and radiochemical purity. [(18)F]AlF-3p-C-NETA-TATE displayed good in vitro stability for 4 h in all tested conditions. Finally, [(18)F]AlF-3p-C-NETA-TATE showed excellent pharmacokinetic properties comparable with the results obtained for [(18)F]AlF-NOTA-Octreotide. Conclusions: 3p-C-NETA is a versatile chelator that can be used for both diagnostic applications (Al(18)F) and targeted radionuclide therapy ((213)Bi, (177)Lu, (161)Tb). It has the potential to be the new theranostic chelator of choice for clinical applications in nuclear medicine. Ivyspring International Publisher 2022-08-08 /pmc/articles/PMC9373814/ /pubmed/35966589 http://dx.doi.org/10.7150/thno.75336 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Ahenkorah, Stephen
Murce, Erika
Cawthorne, Christopher
Ketchemen, Jessica Pougoue
Deroose, Christophe M.
Cardinaels, Thomas
Seimbille, Yann
Fonge, Humphrey
Gsell, Willy
Bormans, Guy
Ooms, Maarten
Cleeren, Frederik
3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
title 3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
title_full 3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
title_fullStr 3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
title_full_unstemmed 3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
title_short 3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
title_sort 3p-c-neta: a versatile and effective chelator for development of al(18)f-labeled and therapeutic radiopharmaceuticals
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373814/
https://www.ncbi.nlm.nih.gov/pubmed/35966589
http://dx.doi.org/10.7150/thno.75336
work_keys_str_mv AT ahenkorahstephen 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT murceerika 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT cawthornechristopher 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT ketchemenjessicapougoue 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT deroosechristophem 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT cardinaelsthomas 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT seimbilleyann 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT fongehumphrey 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT gsellwilly 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT bormansguy 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT oomsmaarten 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals
AT cleerenfrederik 3pcnetaaversatileandeffectivechelatorfordevelopmentofal18flabeledandtherapeuticradiopharmaceuticals